Cargando…
Factors Associated with Fatality during the Intensive Phase of Anti-Tuberculosis Treatment
OBJECTIVE: To determine the case-fatality rate (CFR) at the end of the intensive phase of tuberculosis (TB) treatment, and factors associated with fatality. METHODS: TB patients diagnosed between 2006 and 2013 were followed-up during treatment. We computed the CFR at the end of the intensive phase o...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972388/ https://www.ncbi.nlm.nih.gov/pubmed/27487189 http://dx.doi.org/10.1371/journal.pone.0159925 |
_version_ | 1782446235731361792 |
---|---|
author | Rodrigo, T. Casals, M. Caminero, J. A. García-García, J. M. Jiménez-Fuentes, M. A. Medina, J. F. Millet, J. P. Ruiz-Manzano, J. Caylá, J. |
author_facet | Rodrigo, T. Casals, M. Caminero, J. A. García-García, J. M. Jiménez-Fuentes, M. A. Medina, J. F. Millet, J. P. Ruiz-Manzano, J. Caylá, J. |
author_sort | Rodrigo, T. |
collection | PubMed |
description | OBJECTIVE: To determine the case-fatality rate (CFR) at the end of the intensive phase of tuberculosis (TB) treatment, and factors associated with fatality. METHODS: TB patients diagnosed between 2006 and 2013 were followed-up during treatment. We computed the CFR at the end of the intensive phase of TB treatment, and the incidence of death per 100 person-days (pd) of follow-up. We performed survival analysis using the Kaplan-Meier method and Cox regression, and calculate hazard ratios (HR) and 95% confidence intervals (CI). RESULTS: A total of 5,182 patients were included, of whom 180 (3.5%) died; 87 of these deaths (48.3%) occurred during the intensive phase of treatment, with a CFR of 1.7%. The incidence of death was 0.028/100 pd. The following factors were associated with death during the intensive phase: being >50 years (HR = 36.9;CI:4.8–283.4); being retired (HR = 2.4;CI:1.1–5.1); having visited the emergency department (HR = 3.1;CI:1.2–7.7); HIV infection (HR = 3.4;CI:1.6–7.2); initial standard treatment with 3 drugs (HR = 2.0;CI:1.2–3.3) or non-standard treatments (HR = 2.68;CI:1.36–5.25); comprehension difficulties (HR = 2.8;CI:1.3–6.1); and smear-positive sputum (HR = 2.3-CI:1.0–4.8). CONCLUSION: There is a non-negligible CFR during the intensive phase of TB, whose reduction should be prioritised. The CFR could be a useful indicator for evaluating TB programs. |
format | Online Article Text |
id | pubmed-4972388 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-49723882016-08-18 Factors Associated with Fatality during the Intensive Phase of Anti-Tuberculosis Treatment Rodrigo, T. Casals, M. Caminero, J. A. García-García, J. M. Jiménez-Fuentes, M. A. Medina, J. F. Millet, J. P. Ruiz-Manzano, J. Caylá, J. PLoS One Research Article OBJECTIVE: To determine the case-fatality rate (CFR) at the end of the intensive phase of tuberculosis (TB) treatment, and factors associated with fatality. METHODS: TB patients diagnosed between 2006 and 2013 were followed-up during treatment. We computed the CFR at the end of the intensive phase of TB treatment, and the incidence of death per 100 person-days (pd) of follow-up. We performed survival analysis using the Kaplan-Meier method and Cox regression, and calculate hazard ratios (HR) and 95% confidence intervals (CI). RESULTS: A total of 5,182 patients were included, of whom 180 (3.5%) died; 87 of these deaths (48.3%) occurred during the intensive phase of treatment, with a CFR of 1.7%. The incidence of death was 0.028/100 pd. The following factors were associated with death during the intensive phase: being >50 years (HR = 36.9;CI:4.8–283.4); being retired (HR = 2.4;CI:1.1–5.1); having visited the emergency department (HR = 3.1;CI:1.2–7.7); HIV infection (HR = 3.4;CI:1.6–7.2); initial standard treatment with 3 drugs (HR = 2.0;CI:1.2–3.3) or non-standard treatments (HR = 2.68;CI:1.36–5.25); comprehension difficulties (HR = 2.8;CI:1.3–6.1); and smear-positive sputum (HR = 2.3-CI:1.0–4.8). CONCLUSION: There is a non-negligible CFR during the intensive phase of TB, whose reduction should be prioritised. The CFR could be a useful indicator for evaluating TB programs. Public Library of Science 2016-08-03 /pmc/articles/PMC4972388/ /pubmed/27487189 http://dx.doi.org/10.1371/journal.pone.0159925 Text en © 2016 Rodrigo et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Rodrigo, T. Casals, M. Caminero, J. A. García-García, J. M. Jiménez-Fuentes, M. A. Medina, J. F. Millet, J. P. Ruiz-Manzano, J. Caylá, J. Factors Associated with Fatality during the Intensive Phase of Anti-Tuberculosis Treatment |
title | Factors Associated with Fatality during the Intensive Phase of Anti-Tuberculosis Treatment |
title_full | Factors Associated with Fatality during the Intensive Phase of Anti-Tuberculosis Treatment |
title_fullStr | Factors Associated with Fatality during the Intensive Phase of Anti-Tuberculosis Treatment |
title_full_unstemmed | Factors Associated with Fatality during the Intensive Phase of Anti-Tuberculosis Treatment |
title_short | Factors Associated with Fatality during the Intensive Phase of Anti-Tuberculosis Treatment |
title_sort | factors associated with fatality during the intensive phase of anti-tuberculosis treatment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972388/ https://www.ncbi.nlm.nih.gov/pubmed/27487189 http://dx.doi.org/10.1371/journal.pone.0159925 |
work_keys_str_mv | AT rodrigot factorsassociatedwithfatalityduringtheintensivephaseofantituberculosistreatment AT casalsm factorsassociatedwithfatalityduringtheintensivephaseofantituberculosistreatment AT camineroja factorsassociatedwithfatalityduringtheintensivephaseofantituberculosistreatment AT garciagarciajm factorsassociatedwithfatalityduringtheintensivephaseofantituberculosistreatment AT jimenezfuentesma factorsassociatedwithfatalityduringtheintensivephaseofantituberculosistreatment AT medinajf factorsassociatedwithfatalityduringtheintensivephaseofantituberculosistreatment AT milletjp factorsassociatedwithfatalityduringtheintensivephaseofantituberculosistreatment AT ruizmanzanoj factorsassociatedwithfatalityduringtheintensivephaseofantituberculosistreatment AT caylaj factorsassociatedwithfatalityduringtheintensivephaseofantituberculosistreatment AT factorsassociatedwithfatalityduringtheintensivephaseofantituberculosistreatment |